[go: up one dir, main page]

DE60043624D1 - DNA-Impfung zur Behandlung von Autoimmunerkrankungen - Google Patents

DNA-Impfung zur Behandlung von Autoimmunerkrankungen

Info

Publication number
DE60043624D1
DE60043624D1 DE60043624T DE60043624T DE60043624D1 DE 60043624 D1 DE60043624 D1 DE 60043624D1 DE 60043624 T DE60043624 T DE 60043624T DE 60043624 T DE60043624 T DE 60043624T DE 60043624 D1 DE60043624 D1 DE 60043624D1
Authority
DE
Germany
Prior art keywords
treatment
autoimmune diseases
dna vaccine
vaccination
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043624T
Other languages
English (en)
Inventor
Lawrence Steinman
Pedro Jose Ruiz
Stanford Garren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R UNIVERSITY
Original Assignee
R UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R UNIVERSITY filed Critical R UNIVERSITY
Application granted granted Critical
Publication of DE60043624D1 publication Critical patent/DE60043624D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60043624T 1999-03-12 2000-03-10 DNA-Impfung zur Behandlung von Autoimmunerkrankungen Expired - Lifetime DE60043624D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12

Publications (1)

Publication Number Publication Date
DE60043624D1 true DE60043624D1 (de) 2010-02-11

Family

ID=23019424

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60023673T Expired - Lifetime DE60023673T2 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen
DE60043624T Expired - Lifetime DE60043624D1 (de) 1999-03-12 2000-03-10 DNA-Impfung zur Behandlung von Autoimmunerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60023673T Expired - Lifetime DE60023673T2 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen

Country Status (9)

Country Link
EP (3) EP1621208B1 (de)
JP (1) JP2003508346A (de)
AT (2) ATE453404T1 (de)
CA (1) CA2363269C (de)
DE (2) DE60023673T2 (de)
DK (2) DK1168923T3 (de)
ES (2) ES2338890T3 (de)
PT (1) PT1621208E (de)
WO (1) WO2000053019A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533294A (en) * 2001-11-21 2007-06-29 Univ Leland Stanford Junior Polynucleotide therapy for diabetes associated with self-proteins, -polypeptides and -peptides
CA2669304C (en) 2006-11-30 2016-10-25 Medipost Co., Ltd. Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
CN100571786C (zh) * 2007-03-26 2009-12-23 中国农业大学 一种预防和/或治疗自身免疫疾病的疫苗
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
WO2012105813A2 (en) 2011-02-02 2012-08-09 Medipost Co., Ltd. Use of icam-1 for prevention or treatment of neurological diseases
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
KR20170034701A (ko) 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
AU3225097A (en) * 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease

Also Published As

Publication number Publication date
EP2177228A1 (de) 2010-04-21
EP1621208A1 (de) 2006-02-01
EP1168923A4 (de) 2002-06-26
ES2251974T3 (es) 2006-05-16
PT1621208E (pt) 2010-04-07
JP2003508346A (ja) 2003-03-04
CA2363269A1 (en) 2000-09-14
DE60023673D1 (de) 2005-12-08
ATE308244T1 (de) 2005-11-15
DK1168923T3 (da) 2006-03-20
ATE453404T1 (de) 2010-01-15
EP1168923A1 (de) 2002-01-09
DE60023673T2 (de) 2006-07-20
EP1621208B1 (de) 2009-12-30
WO2000053019A1 (en) 2000-09-14
EP1168923B1 (de) 2005-11-02
ES2338890T3 (es) 2010-05-13
CA2363269C (en) 2012-06-12
DK1621208T3 (da) 2010-05-10

Similar Documents

Publication Publication Date Title
DE60043624D1 (de) DNA-Impfung zur Behandlung von Autoimmunerkrankungen
UA85371C2 (ru) Модифицированный вирус коровьей оспы ankara для вакцинации новорожденных
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
EP1567155A4 (de) Verabreichung teilgereifterdendritischer zellen in vitro zur behandlung von tumoren
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
Harman et al. The horse as a model for the study of cutaneous wound healing
DE3684732D1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
BR0012748A (pt) Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino
DE69737969D1 (de) Dns-impfung zur einleitung einer suppressiven t-zell-antwort
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
ATE512668T1 (de) Allogenes tumortherapeutikum
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
JP2006514034A5 (de)
PL1778833T3 (pl) Sposoby stosowania komórek regeneracyjnych w celu przyspieszania gojenia się ran
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
PT858345E (pt) Uso de muteinas de citocinas do tipo selvagem como imunogenios
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
DE60033397D1 (de) Methode zur steigerung der produktionsleistung in tieren
ATE446767T1 (de) Gm-csf zur behandlung von morbus crohn

Legal Events

Date Code Title Description
8364 No opposition during term of opposition